Lataa...
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
The clinical success of anti-CD20 monoclonal antibody (mAb)-mediated B cell depletion therapy has contributed to the understanding of B cells as major players in several autoimmune diseases. The first therapeutic anti-CD20 mAb, rituximab, is a murine–human chimera to which many patients develop anti...
Tallennettuna:
| Julkaisussa: | Auto Immun Highlights |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer International Publishing
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5688039/ https://ncbi.nlm.nih.gov/pubmed/29143151 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13317-017-0100-y |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|